These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 35677166)
1. The Prognostic Utility of Li C; Yu H; Chen X; Han S; Peng S; Lei T; Yang H Front Oncol; 2022; 12():772773. PubMed ID: 35677166 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. Jeon YW; O JH; Park KS; Min GJ; Park SS; Yoon JH; Eom KS; Min CK; Cho SG Br J Haematol; 2020 Mar; 188(6):860-871. PubMed ID: 31733125 [TBL] [Abstract][Full Text] [Related]
3. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma. Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092 [TBL] [Abstract][Full Text] [Related]
4. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study. Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with Wu W; Zhao L; Wang Y; Chen P; Yuan X; Miao L; Zhu Y; Mao J; Cai Z; Ji Y; Wang L; Jia T Curr Probl Cancer; 2024 Feb; 48():101066. PubMed ID: 38364336 [TBL] [Abstract][Full Text] [Related]
6. Interim FDG Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
8. Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients. Nyilas R; Farkas B; Bicsko RR; Magyari F; Pinczes LI; Illes A; Gergely L Int J Hematol; 2019 Sep; 110(3):331-339. PubMed ID: 31228077 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Geng H; Lian K; Zhang W Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089 [TBL] [Abstract][Full Text] [Related]
10. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995 [TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of PET-CT in patients with diffuse large B-cell lymphoma]. Ding C; Li T; Sun J; Yang W; Ding Q; Xu X Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):923-7. PubMed ID: 25623768 [TBL] [Abstract][Full Text] [Related]
12. [Values of Different Evaluation Criteria of Interim Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288 [TBL] [Abstract][Full Text] [Related]
13. Interim Jiang M; Chen P; Ruan X; Ye X; Pan Y; Zhang J; Huang Q; Zhou W; Wu H; Wang Q Oncol Lett; 2017 Dec; 14(6):6715-6723. PubMed ID: 29344120 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197 [TBL] [Abstract][Full Text] [Related]
15. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359 [TBL] [Abstract][Full Text] [Related]
16. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model. Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of baseline Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of whole-body dynamic Yin J; Wang H; Zhu G; Chen N; Khan MI; Zhao Y Heliyon; 2023 Sep; 9(9):e19749. PubMed ID: 37809527 [TBL] [Abstract][Full Text] [Related]
19. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082 [TBL] [Abstract][Full Text] [Related]
20. Value of Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]